Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a novel formulation of Pfizer's Neurontin that is dosed once a day would earn a 50 percent patient share in the treatment of postherpetic neuralgia, according to surveyed U.S. neurologists. In Europe, such an agent would earn a patient share of 40 percent, according to surveyed European neurologists. Such a drug would become patient-share leader both in the U.S. and Europe's postherpetic neuralgia market in 2013.

The new report entitled Postherpetic Neuralgia: The Greatest Opportunities Are Improved Safety and Tolerability also finds that interviewed experts' concern regarding the need to manage the pain associated with NeurogesX/Astellas's Qutenza administration prevents the drug from earning Decision Resources' proprietary clinical gold standard status for the treatment of postherpetic neuralgia. Great commercial opportunity exists for Qutenza which, like Endo/Elan/Grunenthal's Lidoderm (the current and future clinical gold standard), offers analgesic efficacy comparable to that of sales-leading Lyrica and is devoid of systemic side effects.

"Although experts recognize the long-term efficacy of a single administration of Qutenza as a significant advantage, they cite the need to manage the transient pain associated with the drug's administration as a significant disadvantage. In the balance of these attributes however, experts consider Qutenza a therapeutic option that compares favorably with Lidoderm," stated Decision Resources Analyst Sami Fam, Ph.D. "We believe Qutenza will have tremendous commercial opportunity should experts' perception of its ease of administration improve once they become familiar with the drug."

About the Report

Postherpetic Neuralgia: The Greatest Opportunities Are Improved Safety and Tolerability is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Christopher Comfort   Decision Resources, Inc.   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,
ccomfort@dresources.com

Rheumatologists Are Eager to Use Roche-Genentech's ACTEMRA, According to New Study by BioTrends

View Now